Brokerages forecast that Colgate-Palmolive (NYSE:CL) will report $3.93 billion in sales for the current quarter, Zacks reports. Six analysts have issued estimates for Colgate-Palmolive’s earnings, with estimates ranging from $3.87 billion to $4.04 billion. Colgate-Palmolive reported sales of $3.97 billion during the same quarter last year, which would suggest a negative year-over-year growth rate of 1%. The business is scheduled to report its next earnings report on Friday, October 26th.

On average, analysts expect that Colgate-Palmolive will report full year sales of $15.68 billion for the current year, with estimates ranging from $15.57 billion to $15.89 billion. For the next year, analysts anticipate that the company will post sales of $15.90 billion per share, with estimates ranging from $15.60 billion to $16.42 billion. Zacks’ sales calculations are an average based on a survey of research firms that cover Colgate-Palmolive.

Colgate-Palmolive (NYSE:CL) last issued its earnings results on Friday, July 27th. The company reported $0.77 EPS for the quarter, hitting the consensus estimate of $0.77. The company had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.91 billion. Colgate-Palmolive had a return on equity of 2,494.79% and a net margin of 13.97%. The business’s revenue was up 1.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.72 EPS.

CL has been the subject of several research reports. Citigroup decreased their target price on Colgate-Palmolive from $70.00 to $68.00 and set a “neutral” rating for the company in a research report on Tuesday, July 31st. Wells Fargo & Co lowered Colgate-Palmolive to a “hold” rating in a research report on Tuesday, July 17th. Morgan Stanley decreased their target price on Colgate-Palmolive from $69.00 to $67.00 and set an “equal weight” rating for the company in a research report on Thursday, June 21st. Stifel Nicolaus decreased their target price on Colgate-Palmolive from $75.00 to $73.00 and set a “hold” rating for the company in a research report on Monday, July 23rd. Finally, ValuEngine upgraded Colgate-Palmolive from a “sell” rating to a “hold” rating in a research report on Tuesday, July 31st. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $72.33.

Shares of CL opened at $68.26 on Wednesday. The company has a market capitalization of $59.00 billion, a PE ratio of 23.78, a PEG ratio of 3.04 and a beta of 0.73. The company has a quick ratio of 0.74, a current ratio of 1.06 and a debt-to-equity ratio of -34.49. Colgate-Palmolive has a 52 week low of $61.28 and a 52 week high of $77.91.

Colgate-Palmolive declared that its board has initiated a share buyback plan on Monday, June 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the company to reacquire up to 9% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, November 15th. Investors of record on Friday, October 19th will be given a dividend of $0.42 per share. The ex-dividend date is Thursday, October 18th. This represents a $1.68 dividend on an annualized basis and a yield of 2.46%. Colgate-Palmolive’s dividend payout ratio is currently 58.54%.

In other Colgate-Palmolive news, VP Justin Skala sold 90,069 shares of the business’s stock in a transaction on Thursday, August 2nd. The stock was sold at an average price of $66.36, for a total transaction of $5,976,978.84. Following the completion of the transaction, the vice president now owns 65,061 shares in the company, valued at approximately $4,317,447.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Philip G. Shotts sold 462 shares of the business’s stock in a transaction on Tuesday, September 11th. The stock was sold at an average price of $67.05, for a total value of $30,977.10. Following the transaction, the vice president now owns 41,250 shares of the company’s stock, valued at approximately $2,765,812.50. The disclosure for this sale can be found here. Insiders have sold a total of 415,279 shares of company stock valued at $27,384,156 in the last 90 days. Insiders own 1.02% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. DF Dent & Co. Inc. raised its position in shares of Colgate-Palmolive by 7.1% during the second quarter. DF Dent & Co. Inc. now owns 12,125 shares of the company’s stock worth $786,000 after purchasing an additional 800 shares during the period. Hugh Johnson Advisors LLC raised its position in shares of Colgate-Palmolive by 8.0% during the second quarter. Hugh Johnson Advisors LLC now owns 10,861 shares of the company’s stock worth $704,000 after purchasing an additional 801 shares during the period. Amalgamated Bank raised its position in shares of Colgate-Palmolive by 0.7% during the first quarter. Amalgamated Bank now owns 110,439 shares of the company’s stock worth $7,916,000 after purchasing an additional 806 shares during the period. CHICAGO TRUST Co NA raised its position in shares of Colgate-Palmolive by 24.5% during the first quarter. CHICAGO TRUST Co NA now owns 4,114 shares of the company’s stock worth $295,000 after purchasing an additional 810 shares during the period. Finally, Buckingham Capital Management Inc. raised its position in shares of Colgate-Palmolive by 2.5% during the first quarter. Buckingham Capital Management Inc. now owns 34,396 shares of the company’s stock worth $2,466,000 after purchasing an additional 849 shares during the period. Institutional investors own 74.48% of the company’s stock.

About Colgate-Palmolive

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. It operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The company offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; personal care products comprising bar and liquid hand soaps, shower gels, shampoos, conditioners, and deodorants and antiperspirants; and home care products, such as laundry and dishwashing detergents, fabric conditioners, household cleaners, and other related products.

Further Reading: How Do I Invest in Dividend Stocks

Get a free copy of the Zacks research report on Colgate-Palmolive (CL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.